Ideal Cure for Hepatitis B Infection: The Target is in Sight

Schweitzer, 2015, Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013, Lancet Lond Engl, 386, 1546, 10.1016/S0140-6736(15)61412-X Stanaway, 2016, The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013, Lancet Lond Engl, 10.1016/S0140-6736(16)30579-7 Dianzani, 1990, The biological basis for clinical use of interferon, J Hepatol, 11, S5, 10.1016/0168-8278(90)90156-L Gish, 2015, Chronic hepatitis B: virology, natural history, current management and a glimpse at future opportunities, Antiviral Res, 121, 47, 10.1016/j.antiviral.2015.06.008 Ghany, 2009, Antiviral resistance and hepatitis B therapy, Hepatol Baltim Md, 49, S174, 10.1002/hep.22900 Ke, 2014, Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysis, PLOS ONE, 9, e98865, 10.1371/journal.pone.0098865 Chang, 2010, Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B, Hepatol Baltim Md, 51, 422, 10.1002/hep.23327 Buti, 2015, Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection, Dig Dis Sci, 60, 1457, 10.1007/s10620-014-3486-7 Lau, 2005, Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B, N Engl J Med, 352, 2682, 10.1056/NEJMoa043470 Idilman, 2015, Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naïve chronic hepatitis B patients in the real-world setting, J Viral Hepat, 22, 504, 10.1111/jvh.12358 Marcellin, 2004, Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B, N Engl J Med, 351, 1206, 10.1056/NEJMoa040431 Nagata, 2016, Off-treatment durability of antiviral response to nucleoside analogues in patients with chronic hepatitis B, BMC Gastroenterol, 16, 38, 10.1186/s12876-016-0454-z Tseng, 2015, Higher lifetime chance of spontaneous surface antigen loss in hepatitis B carriers with genotype C infection, Aliment Pharmacol Ther, 41, 949, 10.1111/apt.13170 Perrillo, 2001, Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease, Gastroenterology, 120, 1009, 10.1053/gast.2001.22461 Raimondo, 2010, A 2010 update on occult hepatitis B infection, Pathol Biol (Paris), 58, 254, 10.1016/j.patbio.2010.02.003 Liu, 2014, Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma, Gut, 63, 1648, 10.1136/gutjnl-2013-305785 Wang, 2016, Recent developments in antivirals against hepatitis B virus, Virus Res, 213, 205, 10.1016/j.virusres.2015.12.014 Bock, 1994, Hepatitis B virus genome is organized into nucleosomes in the nucleus of the infected cell, Virus Genes, 8, 215, 10.1007/BF01703079 Levrero, 2009, Control of cccDNA function in hepatitis B virus infection, J Hepatol, 51, 581, 10.1016/j.jhep.2009.05.022 Wong, 2004, Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients, Hepatol Baltim Md, 40, 727, 10.1002/hep.20353 Werle-Lapostolle, 2004, Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy, Gastroenterology, 126, 1750, 10.1053/j.gastro.2004.03.018 Chuaypen, 2016, Kinetics of serum HBsAg and intrahepatic cccDNA during pegylated interferon therapy in patients with HBeAg-positive and HBeAg-negative chronic hepatitis B, J Med Virol Zhang, 2003, Single-cell analysis of covalently closed circular DNA copy numbers in a hepadnavirus-infected liver, Proc Natl Acad Sci U S A, 100, 12372, 10.1073/pnas.2033898100 Jones, 2012, In vitro epsilon RNA-dependent protein priming activity of human hepatitis B virus polymerase, J Virol, 86, 5134, 10.1128/JVI.07137-11 Yang, 2014, Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance, Emerg Microbes Infect, 3, e64, 10.1038/emi.2014.64 Rehermann, 2003, Immune responses in hepatitis B virus infection, Semin Liver Dis, 23, 21, 10.1055/s-2003-37586 Curry, 2000, The dynamics of the immune response in acute hepatitis B: new lessons using new techniques, Hepatol Baltim Md, 32, 1177, 10.1053/jhep.2000.20121 Wong, 2006, One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels, Antivir Ther, 11, 909, 10.1177/135965350601100704 Wursthorn, 2006, Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B, Hepatol Baltim Md, 44, 675, 10.1002/hep.21282 Hagiwara, 2013, Impact of peginterferon alpha-2b and entecavir hydrate combination therapy on persistent viral suppression in patients with chronic hepatitis B, J Med Virol, 85, 987, 10.1002/jmv.23564 Lucifora, 2014, Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA, Science, 343, 1221, 10.1126/science.1243462 Nowak, 1996, Viral dynamics in hepatitis B virus infection, Proc Natl Acad Sci U S A, 93, 4398, 10.1073/pnas.93.9.4398 Tsiang, 1999, Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy, Hepatol Baltim Md, 29, 1863, 10.1002/hep.510290626 Wolters, 2002, Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B, J Hepatol, 37, 137, 10.1016/S0168-8278(02)00115-0 Fourel, 1994, Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks, J Virol, 68, 8321, 10.1128/JVI.68.12.8321-8330.1994 Thimme, 2003, CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection, J Virol, 77, 68, 10.1128/JVI.77.1.68-76.2003 Bohne, 2007, Adoptive T-cell therapy as a therapeutic option for chronic hepatitis B, J Viral Hepat, 14, 45, 10.1111/j.1365-2893.2007.00913.x Krebs, 2013, T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice, Gastroenterology, 145, 456, 10.1053/j.gastro.2013.04.047 Summers, 2003, Hepatocyte turnover during resolution of a transient hepadnaviral infection, Proc Natl Acad Sci U S A, 100, 11652, 10.1073/pnas.1635109100 Guo, 2000, Apoptosis and regeneration of hepatocytes during recovery from transient hepadnavirus infections, J Virol, 74, 1495, 10.1128/JVI.74.3.1495-1505.2000 Mason, 2005, Clonal expansion of hepatocytes during chronic woodchuck hepatitis virus infection, Proc Natl Acad Sci U S A, 102, 1139, 10.1073/pnas.0409332102 Rebbapragada, 2016, Molecular determinants of GS-9620-dependent TLR7 activation, PLOS ONE, 11, e0146835, 10.1371/journal.pone.0146835 Boucle, 2016, Toward elimination of hepatitis B virus using novel drugs, approaches, and combined modalities, Clin Liver Dis, 20, 737, 10.1016/j.cld.2016.07.001 Cai, 2012, Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation, Antimicrob Agents Chemother, 56, 4277, 10.1128/AAC.00473-12 McClary, 2000, Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines, J Virol, 74, 2255, 10.1128/JVI.74.5.2255-2264.2000 Guidotti, 1996, Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes, Immunity, 4, 25, 10.1016/S1074-7613(00)80295-2 Zhu, 2004, Adenovirus-based gene therapy during clevudine treatment of woodchucks chronically infected with woodchuck hepatitis virus, Virology, 327, 26, 10.1016/j.virol.2004.06.017 Turelli, 2004, Inhibition of hepatitis B virus replication by APOBEC3G, Science, 303, 1829, 10.1126/science.1092066 Stenglein, 2010, APOBEC3 proteins mediate the clearance of foreign DNA from human cells, Nat Struct Mol Biol, 17, 222, 10.1038/nsmb.1744 Kitamura, 2013, Uracil DNA glycosylase counteracts APOBEC3G-induced hypermutation of hepatitis B viral genomes: excision repair of covalently closed circular DNA, PLoS Pathog, 9, e1003361, 10.1371/journal.ppat.1003361 Lin, 2016, Review article: novel therapies for hepatitis B virus cure – advances and perspectives, Aliment Pharmacol Ther, 44, 213, 10.1111/apt.13694 White, 2015, The CRISPR/Cas9 genome editing methodology as a weapon against human viruses, Discov Med, 19, 255 Gish, 2015, Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent, Antiviral Res, 121, 97, 10.1016/j.antiviral.2015.06.019 Weber, 2002, Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model, Antiviral Res, 54, 69, 10.1016/S0166-3542(01)00216-9 Manzoor, 2015, Hepatitis B virus therapy: what's the future holding for us?, World J Gastroenterol, 21, 12558, 10.3748/wjg.v21.i44.12558 Brahmania, 2016, New therapeutic agents for chronic hepatitis B, Lancet Infect Dis, 16, e10, 10.1016/S1473-3099(15)00436-3 Gaggar, 2014, Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: a randomized study, Vaccine, 32, 4925, 10.1016/j.vaccine.2014.07.027 Lobaina, 2015, In vitro stimulation with HBV therapeutic vaccine candidate Nasvac activates B and T cells from chronic hepatitis B patients and healthy donors, Mol Immunol, 63, 320, 10.1016/j.molimm.2014.08.003